Cargando…

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease

INTRODUCTION: For the reduction of PTH levels, two classes of drugs are available in the Brazilian market: non-selective and selective vitamin D receptor activators and calcimimetics. Among the mentioned drugs, the SUS provides oral calcitriol, paricalcitol and cinacalcet. OBJECTIVES: Develop cost-e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ponce, Daniela, Cardoso, Marilia Mastrocolla de Almeida, Rúgolo, Juliana Rodrigues Machado, Molina, Silvana Andrea, de Andrade, Luis Gustavo Modelli, Curado, Daniel da Silva Pereira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Nefrologia 2023
Materias:	Perspectives/Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697162/ https://www.ncbi.nlm.nih.gov/pubmed/37015047 http://dx.doi.org/10.1590/2175-8239-JBN-2022-0126en

Ejemplares similares

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Exploring the COVID-19 Pandemic’s Impact on the Health Technology Assessment Process of the National Commission for the Incorporation of Technologies Into the Brazilian Health System
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2023)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

The future is coming: promising perspectives regarding the use of machine learning in renal transplantation
por: Hannun, Pedro Guilherme Coelho, et al.
Publicado: (2018)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Impact of the COVID-19 Pandemic on Solid Organ Transplant and Rejection Episodes in Brazil’s Unified Healthcare System
por: de Andrade, Luis Gustavo Modelli, et al.
Publicado: (2022)

The conundrum of parathyroidectomy vs cinacalcet for treatment of post-transplant hyperparathyroidism
por: Patel, Rima, et al.
Publicado: (2020)

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison
por: Zawierucha, Jacek, et al.
Publicado: (2019)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score
por: Addad, Vanessa Vilani, et al.
Publicado: (2023)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
por: Jeong, Sohyun, et al.
Publicado: (2016)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
por: Ng, Cheng Han, et al.
Publicado: (2020)

Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
por: Timmons, J. G., et al.
Publicado: (2021)

Successful Early Treatment of Severe Neonatal Hyperparathyroidism With Cinacalcet
por: Thakkar, Keya, et al.
Publicado: (2021)

Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis
por: Dulfer, R. R., et al.
Publicado: (2019)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients
por: Fisher, Marisa M, et al.
Publicado: (2015)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Cinacalcet: A Viable Therapeutic Option for Primary Hyperparathyroidism in the Elderly
por: Abusahmin, Hussam, et al.
Publicado: (2018)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Therapy for persistent hypercalcemic hyperparathyroidism post-renal transplant: cinacalcet versus parathyroidectomy
por: Rivelli, Gabriel Giollo, et al.
Publicado: (2020)

Use of Cinacalcet and (99m)Tc-sestamibi Imaging During Pregnancy
por: Rubin, Mishaela R., et al.
Publicado: (2017)

Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
por: Mawad, Habib, et al.
Publicado: (2017)

Surgery for Renal Hyperparathyroidism in the Era of Cinacalcet: A Single-Center Experience
por: Mogl, M. T., et al.
Publicado: (2020)

A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism
por: Bell, Daniel, et al.
Publicado: (2021)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

Increasing transplantability in Brazil: time to discuss Kidney Paired Donation
por: Bastos, Juliana, et al.
Publicado: (2021)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ik6oglat37ujvlgfi9o3agprqe